BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 2403935)

  • 1. Lipids, cardiovascular disease, and oral contraceptives: a practical perspective.
    Upton GV
    Fertil Steril; 1990 Jan; 53(1):1-12. PubMed ID: 2403935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolic impact of oral contraceptives.
    Krauss RM; Burkman RT
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1177-84. PubMed ID: 1415443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral contraceptives and cardiovascular risk. Taking a safe course of action.
    Derman RJ
    Postgrad Med; 1990 Sep; 88(4):119-22. PubMed ID: 2204902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of three low-dose oral contraceptive formulations on lipid metabolism.
    Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L
    Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of triphasic levonorgestrel in oral contraception: a review of metabolic and hemostatic effects.
    Lachnit-Fixson U
    Gynecol Endocrinol; 1996 Jun; 10(3):207-18. PubMed ID: 8862497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
    Crook D; Godsland IF; Wynn V
    Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lipids, lipoproteins, arterial accidents and oral contraceptives].
    Bakir R; Hilliquin P
    Contracept Fertil Sex (Paris); 1986 Jan; 14(1):81-7. PubMed ID: 12341243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipids and cardiovascular disease: do the findings and therapy apply equally to men and women?
    LaRosa JC
    Womens Health Issues; 1992; 2(2):102-11; discussion 111-3. PubMed ID: 1617306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
    Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
    N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L; Pasinetti E
    Acta Obstet Gynecol Scand; 1995 Jan; 74(1):56-60. PubMed ID: 7856434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins.
    Wynn V; Niththyananthan R
    Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):766-71. PubMed ID: 6801982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of oral contraceptive use with serum lipids and lipoproteins in young women: the Bogalusa Heart Study.
    Greenlund KJ; Webber LS; Srinivasan S; Wattigney W; Johnson C; Berenson GS
    Ann Epidemiol; 1997 Nov; 7(8):561-7. PubMed ID: 9408552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desogestrel- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins.
    Ylikorkala O; Kuusi T; Tikkanen MJ; Viinikka L
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1238-42. PubMed ID: 2960690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptives and lipids.
    Fotherby K
    BMJ; 1989 Apr; 298(6680):1049-50. PubMed ID: 2497884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral contraceptives: a reassessment.
    Derman R
    Obstet Gynecol Surv; 1989 Sep; 44(9):662-8. PubMed ID: 2671844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse influences of alcohol, tobacco, and oral contraceptive use on cardiovascular risk factors during transition to adulthood.
    Croft JB; Freedman DS; Cresanta JL; Srinivasan SR; Burke GL; Hunter SM; Webber LS; Smoak CG; Berenson GS
    Am J Epidemiol; 1987 Aug; 126(2):202-13. PubMed ID: 3605049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.